1. Bardelmeijer, H. A., Ouwehand, M., Buckle, T., Huisman, M. T., Schellens, J. H., Beijnen, J. H., and van Tellingen, O., Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res., 62, 6158–6164 (2002).
2. Bissery, M. C., Preclinical pharmacology of docetaxel. Eur. J. Cancer, 31ASuppl 4, S1–S6 (1995).
3. Bley, H., Fussnegger, B., and Bodmeier, R., Characterization and stability of solid dispersions based on PEG/polymer blends. Int. J. Pharm., 390, 165–173 (2010).
4. Chen, J., Qiu, L., Hu, M., Jin, Y., and Han, J., Preparation, characterization and in vitro evaluation of solid dispersions containing docetaxel. Drug Dev. Ind. Pharm., 34, 588–594 (2008).
5. Chen, Y., Chen, G., Shi, Q. Z., Yu, A. R., Fu, X. D., and Liu, H., Study on self-microemulsifying drug delivery system of docetaxel. China Pharmacist, 12, 1507–1510 (2009).